Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -32.94% is 36% below its 5-year average of -24.26%, around the middle of its 5-year range (-59.46%–-11.69%).
As of the fiscal period ended Tuesday, June 30, 2026. 25.03% above its 12-month average of -43.93%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -32.94%.
RETURN ON EQUITY (ROE)
-32.94%
RETURN ON EQUITY (ROE) AVG TTM
-43.93%
RETURN ON EQUITY (ROE) AVG 3Y
-28.75%
RETURN ON EQUITY (ROE) AVG 5Y
-24.26%
RETURN ON EQUITY (ROE) AVG 10Y
-31.77%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.03%
CURRENT VS 3Y AVG
-14.55%
CURRENT VS 5Y AVG
-35.79%
CURRENT VS 10Y AVG
-3.68%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+21.60%
vs the sector median at left
Xenon Pharmaceuticals Inc.
Market Cap
$3.50B
Return on Equity (ROE)
-32.94%
TTM Avg
-43.93%
3Y Avg
-28.75%
5Y Avg
-24.26%
Market Cap
$3.51B
Return on Equity (ROE)
-12.08%
TTM Avg
-47.33%
3Y Avg
-44.55%
5Y Avg
-54.96%
Market Cap
$3.50B
Return on Equity (ROE)
N/A
TTM Avg
-136.37%
3Y Avg
-87.14%
5Y Avg
-78.77%
Market Cap
$3.48B
Return on Equity (ROE)
-14.60%
TTM Avg
-18.51%
3Y Avg
-18.00%
5Y Avg
-17.65%
Market Cap
$3.56B
Return on Equity (ROE)
-7.50%
TTM Avg
-76.90%
3Y Avg
-65.24%
5Y Avg
-51.68%
Market Cap
$3.57B
Return on Equity (ROE)
8.25%
TTM Avg
3.56%
3Y Avg
-0.85%
5Y Avg
-3.10%
Market Cap
$3.43B
Return on Equity (ROE)
-80.46%
TTM Avg
-68.44%
3Y Avg
592.63%
5Y Avg
329.15%
Market Cap
$3.40B
Return on Equity (ROE)
26.08%
TTM Avg
3.42%
3Y Avg
-20.94%
5Y Avg
-16.18%
Market Cap
$3.39B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | $3.50B | -32.94% | -43.93% | -28.75% | -24.26% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.51B | -12.08% | -47.33% | -44.55% | -54.96% |
| Celcuity Inc. (CELC)vs › | $3.50B | N/A | -136.37% | -87.14% | -78.77% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -14.60% | -18.51% | -18.00% | -17.65% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.56B | -7.50% | -76.90% | -65.24% | -51.68% |
| Veracyte, Inc. (VCYT)vs › | $3.57B | 8.25% | 3.56% | -0.85% | -3.10% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | -80.46% | -68.44% | 592.63% | 329.15% |
| CareDx, Inc (CDNA)vs › | $3.40B | 26.08% | 3.42% | -20.94% | -16.18% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 29.12% | 31.38% | -1.34% | -13.55% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A | 336.99% | 336.99% | 336.99% |
ROE
-32.9%
ROA
-31.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -32.94% |
| 2026-03-31 | -28.64% |
| 2025-12-31 | -59.46% |
| 2025-09-30 | -54.75% |
| 2025-06-30 | -43.89% |
| 2025-03-31 | -35.72% |
| 2024-12-31 | -31.04% |
| 2024-09-30 | -26.75% |
| 2024-06-30 | -23.58% |
| 2024-03-31 | -21.25% |
| 2023-12-31 | -19.66% |
| 2023-09-30 | -27.50% |
| 2023-06-30 | -25.33% |
| 2023-03-31 | -21.46% |
| 2022-12-31 | -17.38% |
| 2022-09-30 | -15.08% |
| 2022-06-30 | -11.69% |
| 2022-03-31 | -15.28% |
| 2021-12-31 | -14.34% |
| 2021-09-30 | -26.37% |
| 2021-06-30 | -22.98% |
| 2021-03-31 | -13.43% |
| 2020-12-31 | -16.83% |
| 2020-09-30 | -15.32% |
| 2020-06-30 | -14.74% |
| 2020-03-31 | -20.08% |
| 2019-12-31 | -45.22% |
| 2019-09-30 | -52.00% |
| 2019-06-30 | -53.50% |
| 2019-03-31 | -45.59% |
| 2018-12-31 | -33.40% |
| 2018-09-30 | -30.59% |
| 2018-06-30 | -54.05% |
| 2018-03-31 | -94.54% |
| 2017-12-31 | -85.45% |
| 2017-09-30 | -66.15% |
| 2017-06-30 | -56.72% |
| 2017-03-31 | -47.65% |
| 2016-12-31 | -35.99% |
| 2016-09-30 | -30.20% |
| 2016-06-30 | -32.37% |
| 2016-03-31 | -16.95% |
| 2015-12-31 | -17.73% |
| 2015-09-30 | -8.78% |
| 2015-06-30 | 11.43% |
| 2015-03-31 | 10.76% |
| 2014-12-31 | 17.89% |
| 2014-09-30 | 40.90% |
| 2014-06-30 | 42.41% |
| 2014-03-31 | 42.57% |
| 2013-12-31 | 36.87% |
| 2013-06-30 | -18.64% |
